Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO).

Roila F, Fumi G, Ruggeri B, Antonuzzo A, Ripamonti C, Fatigoni S, Cavanna L, Gori S, Fabi A, Marzano N, Graiff C, De Sanctis V, Mirabile A, Serpentini S, Bocci C, Pino MS, Cilenti G, Verusio C, Ballatori E; NICSO (Network Italiano per le Cure di Supporto in Oncologia).

Support Care Cancer. 2019 Mar;27(3):1041-1047. doi: 10.1007/s00520-018-4393-9. Epub 2018 Aug 6.

PMID:
30084104
2.

Conflict of interest among Italian medical oncologists: a national survey.

DeCensi A, Numico G, Ballatori E, Artioli F, Clerico M, Fioretto L, Livellara V, Ruggeri B, Tomirotti M, Verusio C, Roila F; Italian College of Chief Medical Oncologists (CIPOMO).

BMJ Open. 2018 Jun 30;8(6):e020912. doi: 10.1136/bmjopen-2017-020912.

3.

Fatigue, a major still underestimated issue.

Ripamonti CI, Antonuzzo A, Bossi P, Cavalieri S, Roila F, Fatigoni S.

Curr Opin Oncol. 2018 Jul;30(4):219-225. doi: 10.1097/CCO.0000000000000451. Review.

PMID:
29877886
4.

Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis.

Di Maio M, Baratelli C, Bironzo P, Vignani F, Bria E, Sperti E, Marcato M, Roila F.

Crit Rev Oncol Hematol. 2018 Apr;124:21-28. doi: 10.1016/j.critrevonc.2018.02.001. Epub 2018 Feb 7. Review.

PMID:
29548482
5.

Cognitive impairment and chemotherapy: a brief overview.

Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G.

Crit Rev Oncol Hematol. 2017 Oct;118:7-14. doi: 10.1016/j.critrevonc.2017.08.001. Epub 2017 Aug 14. Review.

PMID:
28917271
6.

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.

Bossi P, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Nolè F, Pessi MA, Macchi F, Michellini L, Montanaro F, Roila F.

Ann Oncol. 2017 Oct 1;28(10):2547-2551. doi: 10.1093/annonc/mdx315.

PMID:
28666335
7.

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G.

Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21.

8.

Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use.

Numico G, Fusco V, Franco P, Roila F.

Crit Rev Oncol Hematol. 2017 Mar;111:144-151. doi: 10.1016/j.critrevonc.2017.01.014. Epub 2017 Feb 3. Review.

PMID:
28259289
9.

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015.

Ann Oncol. 2016 Sep;27(suppl 5):v119-v133. No abstract available.

PMID:
27664248
10.

Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.

Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B.

Support Care Cancer. 2017 Jan;25(1):295-296. No abstract available.

PMID:
27624467
11.

2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.

Ruhlmann CH, Jahn F, Jordan K, Dennis K, Maranzano E, Molassiotis A, Roila F, Feyer P.

Support Care Cancer. 2017 Jan;25(1):309-316. Epub 2016 Sep 13. Review.

PMID:
27624464
12.

2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.

Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B.

Support Care Cancer. 2017 Jan;25(1):289-294. Epub 2016 Aug 11. Erratum in: Support Care Cancer. 2017 Jan;25(1):295-296.

PMID:
27510316
13.

MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update.

Molassiotis A, Aapro M, Herrstedt J, Gralla R, Roila F.

Support Care Cancer. 2017 Jan;25(1):267-269. Epub 2016 Aug 8. No abstract available.

PMID:
27501964
14.

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.

Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS.

Support Care Cancer. 2017 Jan;25(1):277-288. Epub 2016 Jul 22. Review.

PMID:
27443154
15.

Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Bossi P, Cortinovis D, Cossu Rocca M, Roila F, Seminara P, Fabi A, Canova S, Verri E, Fatigoni S, Iannace A, Macchi F, Ripamonti C.

J Altern Complement Med. 2016 Jun;22(6):486-8. doi: 10.1089/acm.2015.0315. Epub 2016 Apr 26.

16.

Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study.

Molassiotis A, Lee PH, Burke TA, Dicato M, Gascon P, Roila F, Aapro M.

J Pain Symptom Manage. 2016 Jun;51(6):987-93. doi: 10.1016/j.jpainsymman.2015.12.317. Epub 2016 Feb 16.

17.

Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain.

Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M; Early Strong Opioid Treatment Study (ESOT) Investigators.

J Clin Oncol. 2016 Feb 10;34(5):436-42. doi: 10.1200/JCO.2015.61.0733. Epub 2015 Dec 7. Erratum in: J Clin Oncol. 2017 May 20;35(15):1753.

PMID:
26644526
18.

Chemotherapy-Induced Nausea and Vomiting.

Rapoport BL, Molasiotis A, Raftopoulos H, Roila F.

Biomed Res Int. 2015;2015:457326. doi: 10.1155/2015/457326. Epub 2015 Sep 6. No abstract available.

19.

A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.

Fonte C, Fatigoni S, Roila F.

Crit Rev Oncol Hematol. 2015 Aug;95(2):214-21. doi: 10.1016/j.critrevonc.2015.02.010. Epub 2015 Mar 5. Review.

PMID:
25779971
20.

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.

Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F; Italian Group for Antiemetic Research.

Ann Oncol. 2015 Jun;26(6):1248-53. doi: 10.1093/annonc/mdv132. Epub 2015 Mar 5.

PMID:
25743855
21.

[Cancer-related fatigue].

Fatigoni S, Fumi G, Roila F.

Recenti Prog Med. 2015 Jan;106(1):28-31. doi: 10.1701/1740.18954. Italian.

PMID:
25621777
22.

NICSO: Network Italiano Cure di Supporto in Oncologia--Italian Network for Supportive Care in Oncology.

Roila F, Ripamonti CI, Antonuzzo A, Bossi P.

Support Care Cancer. 2015 Jan;23(1):11-2. doi: 10.1007/s00520-014-2470-2. Epub 2014 Oct 16. No abstract available.

PMID:
25315366
23.

[Update on anticancer drugs].

Roila F, Ballatori E.

Assist Inferm Ric. 2014 Apr-Jun;33(2):97-115. doi: 10.1702/1539.16817. Review. Italian.

PMID:
25002061
24.

Reply to T.L. Ng et al and L. Celio et al.

Roila F, Fatigoni S, Ballatori E.

J Clin Oncol. 2014 Jul 10;32(20):2187-8. doi: 10.1200/JCO.2014.55.8197. Epub 2014 Jun 9. No abstract available.

PMID:
24912894
25.

Renal malignant solitary fibrous tumor with single lymph node involvement: report of unusual metastasis and review of the literature.

Mearini E, Cochetti G, Barillaro F, Fatigoni S, Roila F.

Onco Targets Ther. 2014 May 8;7:679-85. doi: 10.2147/OTT.S51664. eCollection 2014.

26.

Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.

Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M.

J Clin Oncol. 2014 Jan 10;32(2):101-6. doi: 10.1200/JCO.2013.51.4547. Epub 2013 Dec 9.

PMID:
24323030
27.

Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.

Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F.

J Pain Symptom Manage. 2014 May;47(5):839-848.e4. doi: 10.1016/j.jpainsymman.2013.06.012. Epub 2013 Sep 24.

PMID:
24075401
28.

Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis.

Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F.

Crit Rev Oncol Hematol. 2013 Jul;87(1):12-27. doi: 10.1016/j.critrevonc.2012.12.004. Epub 2013 Jan 11. Review.

PMID:
23313021
29.

Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines.

Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group.

Eur J Oncol Nurs. 2012 Dec;16(5):528-34. No abstract available.

PMID:
23304728
30.

Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.

Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii167-73. No abstract available.

PMID:
22997449
31.

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66.

32.

Management of cancer pain: ESMO Clinical Practice Guidelines.

Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii139-54. No abstract available.

PMID:
22997447
33.

Tackling off-label use of anticancer drugs.

Perrone F, de Braud F, Labianca R, Tomino C, Roila F.

J Clin Oncol. 2012 Aug 1;30(22):2800; author reply 2801. doi: 10.1200/JCO.2012.42.9480. Epub 2012 Jul 2. No abstract available.

PMID:
22753903
34.

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F; PEER investigators.

Ann Oncol. 2012 Aug;23(8):1986-92. Epub 2012 Mar 6.

PMID:
22396444
35.

Juvenile papillomatosis of the breast in young male: a case report.

Sanguinetti A, Fioriti L, Brugia M, Roila F, Farabi R, Sidoni A, Avenia N.

G Chir. 2011 Aug-Sep;32(8-9):374-5.

PMID:
22018260
36.

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2011 Sep;22 Suppl 6:vi85-92. doi: 10.1093/annonc/mdr392. No abstract available.

PMID:
21908511
37.

Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines.

Peterson DE, Bensadoun RJ, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2011 Sep;22 Suppl 6:vi78-84. doi: 10.1093/annonc/mdr391. No abstract available. Erratum in: Ann Oncol. 2012 Mar;23(3):810.

38.

Management of cancer pain: ESMO Clinical Practice Guidelines.

Ripamonti CI, Bandieri E, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2011 Sep;22 Suppl 6:vi69-77. doi: 10.1093/annonc/mdr390. No abstract available.

PMID:
21908508
39.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J.

J Clin Oncol. 2011 Apr 10;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859. Epub 2011 Mar 7.

PMID:
21383291
40.

Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: guideline update and results of the Perugia consensus conference.

Roila F, Herrstedt J, Gralla RJ, Tonato M.

Support Care Cancer. 2011 Mar;19 Suppl 1:S63-5. doi: 10.1007/s00520-010-1044-1. Epub 2010 Dec 28. No abstract available.

PMID:
21188425
41.

Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).

Roila F, Warr D, Aapro M, Clark-Snow RA, Einhorn L, Gralla RJ, Herrstedt J, Saito M, Tonato M.

Support Care Cancer. 2011 Mar;19 Suppl 1:S57-62. doi: 10.1007/s00520-010-1039-y. Epub 2010 Dec 5.

PMID:
21132332
42.

Invasive ductal carcinoma arising in ectopic breast tissue of the axilla. Case report and review of the literature.

Sanguinetti A, Ragusa M, Calzolari F, D'Ajello F, Fioriti L, Papini D, Sidoni A, Roila F, Avenia N.

G Chir. 2010 Aug-Sep;31(8-9):383-6. Review.

PMID:
20843442
43.

Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.

Jordan K, Roila F, Molassiotis A, Maranzano E, Clark-Snow RA, Feyer P; MASCC/ESMO.

Support Care Cancer. 2011 Mar;19 Suppl 1:S37-42. doi: 10.1007/s00520-010-0994-7. Epub 2010 Sep 9.

PMID:
20824481
44.

Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.

Feyer PC, Maranzano E, Molassiotis A, Roila F, Clark-Snow RA, Jordan K; MASCC/ESMO.

Support Care Cancer. 2011 Mar;19 Suppl 1:S5-14. doi: 10.1007/s00520-010-0950-6. Epub 2010 Aug 10.

PMID:
20697746
45.

Acute emesis: moderately emetogenic chemotherapy.

Herrstedt J, Rapoport B, Warr D, Roila F, Bria E, Rittenberg C, Hesketh PJ.

Support Care Cancer. 2011 Mar;19 Suppl 1:S15-23. doi: 10.1007/s00520-010-0951-5. Epub 2010 Aug 2.

PMID:
20680356
46.

Prevention and treatment of pandemic influenza in cancer patients.

Francisci D, Labianca R, Roila F.

Ann Oncol. 2010 Dec;21(12):2301-3. doi: 10.1093/annonc/mdq351. Epub 2010 Jul 8. No abstract available.

PMID:
20616196
47.

Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines.

Bovelli D, Plataniotis G, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v277-82. doi: 10.1093/annonc/mdq200. No abstract available.

PMID:
20555097
48.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v274-6. doi: 10.1093/annonc/mdq199. No abstract available.

PMID:
20555096
49.

Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines.

Peterson DE, Bensadoun RJ, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v261-5. doi: 10.1093/annonc/mdq197. No abstract available.

PMID:
20555094
50.

Management of cancer pain: ESMO Clinical Practice Guidelines.

Jost L, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v257-60. doi: 10.1093/annonc/mdq224. No abstract available.

PMID:
20555093

Supplemental Content

Support Center